Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion

Park, Jongyeop; Lee, Seung-Woo; Son, Yengwoo

doi:10.18240/ijo.2016.07.11

Cited by 8 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we collected the resent-onset and treatment-naïve patients, who were at acute phase, and our results were consistent with Tsuiki’s findings. Furthermore, several studies demonstrated that choroidal thickness in RVO eyes decreased significantly following anti-VEGF treatment [12, 13, 16, 37], however, Park Jongyeop and colleagues reported that no SFCT change was found after anti-VEGF treatment [9]. The possible cause of this conflicting result might be the different follow-up period.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Tang

Zhong

et al. 2019

BMC Ophthalmol

View full text Add to dashboard Cite

Background To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. What is more, to compare SFCT and SFCT change between central RVO (CRVO) and branch RVO (BRVO). Methods In the retrospective study, we had collected 36-six treatment-naïve patients with unilateral ME secondary to RVO (including 19 CRVO and 17 BRVO). All patients had received IVR injection after newly diagnosed. The SFCT was measured at the onset and after 2 weeks of IVR injection. Paired t test was performed to compare the SFCT of RVO eyes and fellow eyes, as well as the SFCT of pre-injection and post-injection. In further, independent t test was used to compare SFCT and SFCT change between CRVO eyes and BRVO eyes. Results The mean SFCT at the onset was 326.03 ± 30.86 μm in CRVO eyes, which was significantly thicker than that in contralateral fellow eyes ( p < 0.01, paired t test), and reduced to 294.15 ± 30.83 μm rapidly after 2 weeks of IVR injection ( p < 0.01, paired t test). Similarly, the SFCT in BRVO eyes was significantly thicker than that in contralateral eyes at the onset, and decreased significantly after IVR injection. However, our findings showed that there was no statistically significant difference in SFCT and SFCT reduction after IVR injection between CRVO eyes and BRVO eyes. Conclusions The SFCT in eyes with ME secondary to CRVO and BRVO was significantly thicker than that in fellow eyes, and decreased significantly within a short time in response to a single IVR injection. In further, the study showed that SFCT and SFCT change had no correlation with RVO subtypes.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Besides, SFCT change after anti-VEGF therapy was also contradictory [14, 15]. Most of the studies reported that the SFCT was decreased significantly after anti-VEGF treatment [12, 16], while a few studies reported that SFCT didn’t decrease after anti-VEGF treatment [9]. Thus, these contradictory results warrant further investigation.…”

Section: Introductionmentioning

confidence: 99%

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Tang

Zhong

et al. 2019

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Bevacizumab is administered at a clinically relevant dose of 1.25 mg in cases of advanced DR ( Gudla et al., 2018 ). However, effects of doses up to 2.5 mg have been assessed in animal models and human subjects ( Arevalo et al., 2011 ; Lashay et al., 2020 ; Park et al., 2016 ). Thus, the present study investigated the effect of Bevacizumab below, at and above the clinically relevant doses, on 3D and 2D cultures of RF/6A cells.…”

Section: Discussionmentioning

confidence: 99%

Three-dimensional spheroids of choroid-retinal vascular endothelial cells as an in-vitro model for diabetic retinopathy: Proof-of-concept investigation

Gore

Tiwari

Jahagirdar

et al. 2022

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

“…Previous reports have described changes in retinal vein diameter in patients with BRVO, in whom anti-VEGF injection causes the vasoconstriction of the retinal vein [ 16 , 17 , 18 ]. Here, the number of anti-VEGF injections was not significantly correlated with the diameter of the occluded vein in the BRVO eye ( Table 3 ).…”

Section: Discussionmentioning

confidence: 99%

Deterioration of Retinal Blood Flow Parameters in Branch Retinal Vein Occlusion Measured by Doppler Optical Coherence Tomography Flowmeter

Takahashi

Song

Sogawa

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Doppler optical coherence tomography (DOCT) flowmeter can be used to measure retinal blood flow (RBF) parameters, including vessel diameter, blood velocity, and the absolute value of RBF within 2.0 s. We investigated the RBF parameters in eyes with branch retinal vein occlusion (BRVO) using a DOCT flowmeter. Methods: Seventeen patients with unilateral BRVO were enrolled. All subjects underwent comprehensive ophthalmologic examinations. The RBF parameters were assessed from three veins, i.e., (1) an occluded vein, (2) a non-occluded vein in the BRVO eyes, and (3) an equivalent (superior or inferior) vein in the fellow eye (non-affected vein), using prototype DOCT flowmeter (Topcon, Tokyo, Japan). Moreover, the correlation between RBF parameters and the best corrected visual acuity (BCVA) was examined. We investigated the correlation between (1) the RBF parameters and the time from the initial visit, (2) the RBF parameters and the time from the last injection, and (3) the RBF parameters and the number of anti-vascular endothelial growth factor injections (VEGF). Results: The diameter of the occluded vein (95.9 ± 24.7 µm) was smaller than that of the non-occluded vein (127.9 ± 23.7 µm) and that of the healthy veins (116.4 ± 13.9 µm). The RBF was lower in the occluded veins (4.7 ± 3.7 µL/min) than that in the non-occluded veins (10.3 ± 5.1 µL/min; p < 0.01) and in the fellow eyes (8.6 ± 4.0 µL/min; p = 0.013). In contrast, the blood velocity was not significantly different among the three types of veins. BCVA was correlated with the diameter of the occluded vein (ρ = 0.711, p = 0.001) but not with the RBF and blood velocity. The time from the initial visit, the time from the last injection, and the total number of anti-VEGF injections were not associated with any RBF parameters on the occluded vein. Conclusions: The RBF was significantly lower in the occluded veins than that in the other veins, and the diameter of the occluded vein was significantly smaller than that of the other veins in patients with BRVO. However, neither the time from the initial visit, nor the time from the last injection, nor the number of anti-VEGF injections were correlated with the RBF parameters on the occluded vein.

show abstract

Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion

Abstract: Changes in the SFChT are not statistically significant and not different according to the doses of bevacizumab. The CRAE did not show significant change, however, the CRVE showed significant decrease regardless of the dose.

Cited by 8 publications

References 28 publications

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Three-dimensional spheroids of choroid-retinal vascular endothelial cells as an in-vitro model for diabetic retinopathy: Proof-of-concept investigation

Deterioration of Retinal Blood Flow Parameters in Branch Retinal Vein Occlusion Measured by Doppler Optical Coherence Tomography Flowmeter

Contact Info

Product

Resources

About